Summary of Gene Therapies Outlook - ref #GB000028
Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook
GBI Research’s report, "Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. It includes not only the insertion of a gene into the cell for expression, but also gene silencing with RNA interference (RNAi) and antisense RNA, aptamers (DNA or RNA polymers which bind to a protein target), and oncolytic viruses.
Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow. Gene therapies only account for a marginal market share and many efficacy and safety concerns remain unaddressed. However, the pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage. This indicates that although gene therapies are beginning to reach the market after two decades of research in humans, the majority remain in relatively early development.
This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.
Scope
Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success -
- Why do gene therapies still occupy only a minimal market share in their respective indications?
- What can be learned from the gene therapies that have already reached the market?
A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies -
- What are the relative advantages and disadvantages of each vector type and which hold the most promise?
- What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?
The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene -
- In which therapy areas is there the highest level of R&D activity for gene therapies?
- At which stage of development does the majority of pipeline gene therapies reside?
- What is the proportion of the pipeline occupied by each intervention and vector type overall?
A number of companies are currently actively developing pipeline gene therapies, including private, public and institutional enterprises -
- How do gene therapies fit into the overall portfolios of these companies?
- What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?
Key Reasons to Purchase
This report will allow you to -
- Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen.
- Assess the pipeline for gene therapies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, infectious diseases, central nervous system disorders, and genetic disorders.
- Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. Understand the level of involvement on the part of big pharma companies, and the extent to which gene therapies fit into the overall portfolios of companies in this field. Additionally, a highly granular breakdown of companies developing multiple gene therapies is provided.
Publisher: CBR Pharma Insights
Publication date: September 2015
You need to agree to the Terms and Conditions before placing your order
Terms and Conditions
GLOBALDATA TERMS AND CONDITIONS
Single Copy Report Products
GlobalData Ltd (“Holding Company”), a company registered in England with the company number 05968121 and registered office at John Carpenter House, John Carpenter Street, London, EC4Y 0AN, United Kingdom. These terms and conditions and the Order Form comprise the agreement pursuant to which Company provides the Product (defined below) to you ("Agreement"). "We", "us", "our" or “GlobalData” refers to Company. "You" or "your" refers to the person who (or on whose behalf) an Order is placed and includes your legal successors and permitted assigns.
1. Order Forms: Order Forms shall only be binding when accepted by us. You shall not cancel or amend an Order Form unless we have given our prior written consent. We shall assume that any person who places an Order Form on your behalf can bind you legally.
2. Ownership: The legal and beneficial interest in all copyrights, patents, trade marks, service marks, design rights (whether registered or unregistered), database rights, proprietary information rights and all other proprietary rights as may exist anywhere in the world together with applications associated with any such rights ("Intellectual Property Rights") relating to the Product belong to us, the holding company, or our licensors, as the case may be, at all times. You obtain no ownership rights in the Product or any of the Intellectual Property Rights pursuant to or arising out of this Agreement.
3. Grant of License: We grant you a non exclusive, non transferable license to use the products described in the Order Form ("Product"). You warrant that you shall only use the Product for your business purposes in accordance with this agreement and shall not, without our prior written consent, make available, copy, reproduce, retransmit, disseminate, sell, license, distribute, publish, broadcast or otherwise circulate the Product (or any part of it) to any person other than in accordance with these terms and conditions. You further warrant that you shall comply with all applicable laws and regulations and shall not knowingly use the Product for any improper or unlawful purposes.
4. License: Unless stated otherwise on the Order Form the Product is licensed to you on a single user basis. Only the user named on the Order Form as the customer may use the product as outlined in this agreement. Additional user licenses may be purchased by you at our prevailing standard list prices for single users or by the purchase of a site wide or enterprise wide license. You warrant that you will use appropriate controls to ensure that the license is not breached by you or by other users and agree that any breach may cause us irrepreable harm. You agree we have the right to charge additional fees for unauthorized usage in line with our standard list prices. This clause survives termination of the Agreement.
5. Fees and Payment Terms: Payment is due in full prior to delivery of any product. We shall invoice you for fees payable by you to us under this Agreement ("Fees") upon our acceptance of an Order Form. Unless indicated otherwise on the Order Form you will pay all invoices on receipt of that invoice. We may issue the invoice in print and/or electronic form. Unless expressly provided the fees exclude any sales, use, excise, or other applicable taxes. You will pay or reimburse us for any such taxes for which either party may become held responsible for. A fee for late payment will be assessed equal to the lower of one and one half percent (1.5%) per month and the maximum permitted by law. In addition you agree that all sales are final and that you may not request a refund. We reserve the right, for any reason whatsoever, to withold delivery of the Product to you until payment has been received in full.
6. Warranties: We shall use best endeavors to ensure the Product is provided to you in accordance with any specifications set out in the Order Form and accepted by us. We do not warrant that the Product will meet your requirements or that it will be complete, error free or delivered without interruption. Findings, conclusions and recommendations in the Product are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, we can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect. Except as expressly set out in this Agreement, all express or implied representations, warranties, conditions and undertakings are excluded to the maximum extent permissible by law. You assume sole responsibility for the selection, suitability and use of the Product and acknowledge that except as stated above we do not provide any additional warranties or guarantees relating to the Product. This clause survives termination of the Agreement.
7. Indemnification. Generally. We and You (“Both Parties”) will, to the extent permitted by law, indemnify, defend and hold harmless the other party from and against any and all claims, demands, complaints, or actions of third parties (including employees of the parties) arising from or relating to this agreement, including personal injury, death and property damage to the extent caused or arising out of the violation of law, gross negligence, fraud, willful misconduct or breach of this agreement. In the event that both parties are at fault they will indemnify each other in proportion to their relative negligence. In addition we will indemnify, defend and hold harmless, you from and against any and all claims, demands, complaints or actions of third parties (including employees of the parties) arising from or relating to this agreement brought against you alleging that the product infringe any patent, copyright, trademark, trade secret or other intellectual property right. Our obligations under this section are conditioned on you i) Promptly notifying us of any claim, ii) Granting us sole control over the defense and settlement of the action. iii) Reasonably cooperating with us in connection with such action at our expense, iv) Abetting no such claim, demand, complaint or action v) Neither modifying or using the product nor breaching this agreement in a manner for which no infringement would have occurred. If the product becomes or in our opinion is likely to become the subject of such a claim, then in lieu of the indemnity we may, at our expense, i) procure you the right to license using or receiving the product free of any such liability, ii) replace or modify in whole or part the product to make them non-infringing without degradation or iii) refund you a pro-rata portion of the fee.
8. Limitation of liability: Neither party shall be liable under this agreement to the other party for indirect, special, exemplary, punitive or consequential damages including without limitation loss of goodwill, whether arising from negligence, breach of contract or otherwise. Our liability in contract, tort or otherwise arising out of or in connection with the Agreement shall in respect of any one or more incidents not exceed the total fees received by us from you for the Product in the 12 months prior to the date the incident occurs. This clause shall survive termination of the Agreement.
9. Confidentiality: Neither party shall, except as required to perform our and / or your respective rights and obligations, use, copy, adapt, alter, disclose to any third party or part with possession of any information or data of the other party which is disclosed or otherwise comes into our or your possession directly or indirectly as a result of these Terms and which is of a confidential nature, in writing marked confidential or, if disclosed orally, reduced to writing and marked confidential within 30 days of the date of such disclosure ("Information"). This obligation shall not apply to Information:
a. the receiving party can prove was in its possession at the date it was received or obtained; or
b. the receiving party obtains from some person other than us, you or an Affiliate with good legal title thereto; or
c. comes into the public domain otherwise than through the default or negligence of the receiving party; or
d. is independently developed by or for the receiving party.
10. Solicitation. You agree that for a period of twelve (12) months immediately following the delivery of the products purchased, for any reason, whether with or without cause, you shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees, who were involved in the sale, marketing, support or production of the product used, to leave their employment, or attempt to solicit, induce, recruit, encourage or take away employees of the Company.
11. Force Majeure: We shall not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, including but not limited to, earthquake, fire, flood or any other natural disaster, labor dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
12. Further Provisions: The Agreement constitutes the entire understanding between the parties relating to the Product and supersedes all previous agreements and understandings whether oral or written relating to the Product. In the event of any inconsistency between these terms and conditions and the Order, the Order shall prevail. The Agreement may only be varied in writing signed by an authorized representative of each party. Failure at any time to enforce any of these terms and conditions or to require performance by the other party of any such term or condition shall not be construed as a waiver of such provision or affect the right of either party to enforce the same. If any provision is held to be invalid or unenforceable by any tribunal of competent jurisdiction, the remaining provisions shall not be affected and shall be carried out as closely as possible according to the original intent. The Agreement does not confer any rights to or on any third party. The Agreement shall be governed by the laws of England and Wales. The parties irrevocably agree to the exclusive jurisdiction of the Courts of England.
GLOBALDATA TERMS AND CONDITIONS